Advertisement
DNLI vs VIR
Which Stock Would AI Choose? Denali Therapeutics (DNLI) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- Different stages of commercial maturity: Denali recently launched its first approved drug (Avlayah), while Vir remains clinical-stage with no meaningful product revenue yet.
- Distinct therapeutic focus: Denali targets rare genetic and neurodegenerative diseases using blood-brain-barrier technology, whereas Vir focuses on infectious diseases (hepatitis delta) and oncology.
- Momentum diverged recently: Both stocks rallied in 2026, but Denali pulled back in recent weeks after a strong first-half surge, while Vir has shown high volatility around partnership news.
- Cash positions are a shared strength: Denali holds more than $1.1 billion in pro forma cash, and Vir reports roughly $1 billion plus Astellas proceeds, with runway into 2028.
- Risk profiles differ: Denali faces commercial execution and confirmatory-trial risk, while Vir faces binary clinical-trial readouts across 2026 and 2027.
Introduction
Investors evaluating small- and mid-cap biotechnology often weigh scientific promise against near-term catalysts and financial durability. This stock comparison examines DNLI, Denali Therapeutics, and VIR, Vir Biotechnology — two clinical and commercial-stage names whose fortunes hinge on different therapeutic platforms and timelines. Both have attracted attention for breakthrough-adjacent science and strengthened balance sheets, yet their market positioning and recent relative performance tell contrasting stories. Growth-oriented investors and event-driven traders may find this comparison useful for understanding where momentum, catalysts, and execution risk currently sit across the two companies.
DNLI Overview and Recent Performance
Denali Therapeutics is a biopharmaceutical company developing therapies for neurodegenerative and lysosomal storage diseases using its "TransportVehicle" platform, which is designed to carry biologic medicines across the blood-brain barrier. In recent months, the company reached a major milestone with U.S. Food and Drug Administration (FDA) accelerated approval of Avlayah (tividenofusp alfa) for Hunter syndrome (mucopolysaccharidosis type II, or MPS II) — the first new treatment option for the rare condition in roughly two decades.
The commercial launch has driven the company's first product revenue, with roughly $3.6 million in net sales reported in its most recent quarter and management guiding higher for the following period. Denali also monetized a Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million, pushing pro forma cash above $1.1 billion. This regulatory and commercial progress fueled a substantial year-to-date advance, though shares have since pulled back in recent weeks as investors weighed ongoing cash burn and the requirement to confirm Avlayah's clinical benefit in an ongoing global trial. The 52-week trading range and elevated short interest reflect continued debate over valuation.
VIR Overview and Recent Performance
Vir Biotechnology is a clinical-stage biopharmaceutical company developing treatments for serious infectious diseases and cancer. Its pipeline centers on a chronic hepatitis delta program — combining tobevibart and elebsiran — and a portfolio of "PRO-XTEN" dual-masked T-cell engagers (TCEs), a class of cancer therapies that direct immune T-cells to attack tumor cells while a mask limits off-target toxicity.
Recent months brought several significant catalysts. Vir closed a global collaboration with Astellas worth up to $1.7 billion around its prostate cancer candidate VIR-5500, receiving roughly $315 million in combined upfront and equity payments, and later announced a separate collaboration with Gilead covering three solid-tumor candidates. The company also completed a follow-on offering and reported encouraging Phase 2 data showing 88% of evaluable patients reached undetectable virus at week 96. These developments drove a strong year-to-date gain, though the stock remains volatile and has pulled back in recent weeks. Vir expects pivotal Phase 3 ECLIPSE topline data for hepatitis delta in the fourth quarter of 2026, with cash runway into 2028.
Trending AI Robots
For investors seeking a data-driven, systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of the platform's AI Trading Bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific tickers they cover — ranging from short-term momentum strategies to longer-horizon trend-following approaches. Many are designed to remove emotional bias by automating entry, exit, and position-management decisions based on technical and statistical signals. Explore the Trending AI Robots page to see which strategies are currently leading.
Head-to-Head Comparison
The two companies occupy different ends of the biotech spectrum. DNLI has transitioned from a pure platform story to a commercial-stage business, giving investors a tangible revenue line but introducing execution and confirmatory-trial risk. Its value proposition rests on the durability of Avlayah's launch and the broader pipeline, including programs for Sanfilippo syndrome type A and frontotemporal dementia.
VIR, by contrast, remains pre-revenue and depends on near-term clinical readouts and partner milestones. Its risk is more concentrated around binary trial events in hepatitis delta and oncology, though the Astellas and Gilead collaborations offset some financing risk and validate its platform. In terms of sector exposure, Denali is anchored in rare neurology and lysosomal disorders, while Vir spans infectious disease and oncology — each carrying distinct regulatory and competitive dynamics. On recent momentum, both stocks advanced strongly in 2026 before cooling, making relative performance sensitive to catalyst timing rather than a single shared narrative.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely lean toward DNLI at present. The company's confirmed FDA approval, initial commercial traction, and fortified balance sheet provide a comparatively stable foundation and more clearly defined near-term milestones than VIR's heavier reliance on upcoming binary trial readouts. That said, this reflects a probabilistic read on trend and stability rather than a definitive forecast; Vir's partnership-driven catalysts and strong cash runway could shift the relative picture quickly if pivotal data land favorably. The AI framework weighs consistency of trend alongside risk, which currently tilts the balance toward Denali while acknowledging Vir's higher optionality.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and VIR is a Hold.
DNLI's RSI Oscillator ascends from oversold territory
The RSI Indicator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 70 cases where DNLI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +7.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 209 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
DNLI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNLI as a result. In 84 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for DNLI entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.575) is normal, around the industry mean (2.988). P/E Ratio (-6.577) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VIR sees MACD Histogram crosses below signal line
VIR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 36 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 75 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
VIR moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 202 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 115 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (2.988). P/E Ratio (-5.972) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DNLI | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 22 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 60 | 40 | |
P/E GROWTH RATING 1..100 | 22 | 58 | |
SEASONALITY SCORE 1..100 | 15 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (22) in the null industry is somewhat better than the same rating for DNLI (80) in the Biotechnology industry. This means that VIR’s stock grew somewhat faster than DNLI’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that VIR’s stock grew similarly to DNLI’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as DNLI (98) in the Biotechnology industry. This means that VIR’s stock grew similarly to DNLI’s over the last 12 months.
VIR's Price Growth Rating (40) in the null industry is in the same range as DNLI (60) in the Biotechnology industry. This means that VIR’s stock grew similarly to DNLI’s over the last 12 months.
DNLI's P/E Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for VIR (58) in the null industry. This means that DNLI’s stock grew somewhat faster than VIR’s over the last 12 months.
| DNLI | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 77% |
| Advances ODDS (%) | 3 days ago 79% | 3 days ago 76% |
| Declines ODDS (%) | 9 days ago 81% | 9 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 72% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNLI’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- DNLI’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNLI’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).
- DNLI’s TA Score: 5 bullish, 3 bearish.
- VIR’s TA Score: 4 bullish, 4 bearish.
Price Growth
DNLI (@Biotechnology) experienced а +4.53% price change this week, while VIR (@Biotechnology) price change was +1.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -18.10%, and the average quarterly price growth was -15.28%.
Reported Earning Dates
DNLI is expected to report earnings on Nov 05, 2026.
VIR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
DNLI and
Correlation & Price change
A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To DNLI | 1D Price Change % | ||
|---|---|---|---|---|
| DNLI | 100% | -1.32% | ||
| VIR - DNLI | 52% Loosely correlated | -1.58% | ||
| VCYT - DNLI | 50% Loosely correlated | +3.19% | ||
| EDIT - DNLI | 48% Loosely correlated | -2.71% | ||
| BEAM - DNLI | 47% Loosely correlated | -0.36% | ||
| SANA - DNLI | 47% Loosely correlated | -0.42% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -1.58% | ||
| BEAM - VIR | 55% Loosely correlated | -0.36% | ||
| DNLI - VIR | 53% Loosely correlated | -1.32% | ||
| EDIT - VIR | 52% Loosely correlated | -2.71% | ||
| PRME - VIR | 51% Loosely correlated | -2.81% | ||
| RCUS - VIR | 51% Loosely correlated | -19.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BPI | 25.95 | 0.52 | +2.06% |
| Grayscale Bitcoin Premium Income ETF | |||
| JADE | 75.52 | 0.06 | +0.07% |
| JPMorgan Active Developing Markets Equity ETF (JADE) | |||
| JFLX | 48.99 | 0.02 | +0.04% |
| JPMorgan Flexible Debt ETF (JFLX) | |||
| XFIV | 46.96 | -0.01 | -0.03% |
| BondBloxx Bloomberg Five Year Target Duration US Treasury ETF (XFIV) | |||
| SPDV | 41.05 | -0.06 | -0.15% |
| AAM S&P 500 High Dividend Value ETF (SPDV) | |||